Pharmacoeconomics applied to chronic hepatitis C
Braz. j. infect. dis
; 10(1): 51-54, Feb. 2006. tab, graf
Article
en En
| LILACS
| ID: lil-428716
Biblioteca responsable:
BR1.1
RESUMO
Life expectancy has increased over the last century as it had never been before. This is the result of a combination of many favorable variables such as level of education, improved socio-economic environment and development of medicine. However, new improvements demand heavy investment. Thus, the incorporation of medical technology became a health and economic issue. The pharmacoeconomic knowledge field is being developed to help in the analysis of medical costs and patient needs. The applies to hepatitic C, a common and chronic worldwide disease. In this article, the authors describe the rational behind this type of health economic analysis and review a hepatitis C model. Overall, in a non-Brazilian scenario, it was demonstrated that peginterferon alfa-2a (40KD) is cost effective in the treatment of HCV disease.
Texto completo:
1
Índice:
LILACS
Asunto principal:
Antivirales
/
Ribavirina
/
Interferón-alfa
/
Hepatitis C Crónica
Tipo de estudio:
Health_economic_evaluation
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Braz. j. infect. dis
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2006
Tipo del documento:
Article